CURE, a website and publishing group, highlighted our organization stressing the importance of clinical trials and their role in pancreatic cancer. Below is an excerpt from the article and link to read more.
With five-year survival rates for pancreatic cancer in the single digits and incidence rising, matching patients to the right clinical trial is a top priority for the Pancreatic Cancer Action Network.

Pancreatic cancer is forecast to surpass colorectal cancer as the second-leading cause of cancer-related deaths around 2020, and experts agree that the best way to forestall this troubling trend is through a robust clinical trials program.

There is perhaps no greater testament to the value of clinical research than the stories of survivors who are helping the Pancreatic Cancer Action Network to spread the word about how these trials represent—more than anything—hope.

“Clinical trials give you your best chance to survive,” stresses Robb Lamont, a lawyer based in Tampa, Fla., who was first diagnosed with pancreatic cancer at age 36. He has since faced four recurrences and credits his participation in a vaccine-based clinical trial for putting his disease back into remission. “Without this clinical trial, I wouldn’t be here today.”

Read more from CURE here.
Read Robb Lamont’s full story here.